



# **N<sup>6</sup>-Methyladenosine (m<sup>6</sup>A)**




**N<sup>6</sup>-methyladenosine  
(m<sup>6</sup>A)** †

# m<sup>6</sup>A is deposited across a wide range of RNA species





# A new.... old phenomenon



# A new.... old phenomenon



Proc. Nat. Acad. Sci. USA  
Vol. 71, No. 10, pp. 3971-3975, October 1974

## Identification of Methylated Nucleosides in Messenger RNA from Novikoff Hepatoma Cells

(RNA methylation/RNA processing/methylnucleoside composition)

RONALD DESROSIERS, KAREN FRIDERICI, AND FRITZ ROTTMAN\*


The Department of Biochemistry, Michigan State University, East Lansing, Mich. 48824




Cell, Vol. 1, No. 1, January 1974, Copyright © 1974 by MIT

## Existence of Methylated Messenger RNA in Mouse L Cells

R. P. Perry and D. E. Kelley  
The Institute for Cancer Research,  
Fox Chase Center for Cancer  
and Medical Sciences  
Philadelphia, Pennsylvania 19111



**N<sup>6</sup>-methyladenosine (m<sup>6</sup>A)**



# A new.... old phenomenon

© 1990 Oxford University Press

Nucleic Acids Research, Vol. 18, No. 19 5735

## Sequence specificity of the human mRNA N6-adenosine methylase *in vitro*

Joan E. Harper\*, Sheila M. Miceli<sup>1</sup>, Richard J. Roberts<sup>1</sup> and James L. Manley  
Department of Biological Sciences, Columbia University, New York, NY 10027 and <sup>1</sup>Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA

Biochem. J. (1992) 288, 233-240 (Printed in Great Britain)

233

## Partial purification of a 6-methyladenine mRNA methyltransferase which modifies internal adenine residues

Martin T. TUCK  
Department of Chemistry and the Programme in Molecular and Cellular Biology, Ohio University, Athens, OH 45701, U.S.A.

THE JOURNAL OF BIOLOGICAL CHEMISTRY  
© 1994 by The American Society for Biochemistry and Molecular Biology, Inc.

Vol. 269, No. 26, Issue of July 1, pp. 17697-17704, 1994  
Printed in U.S.A.

## Characterization and Partial Purification of mRNA N<sup>6</sup>-Adenosine Methyltransferase from HeLa Cell Nuclei

INTERNAL mRNA METHYLATION REQUIRES A MULTISUBUNIT COMPLEX\*

(Received for publication, February 3, 1994, and in revised form, April 25, 1994)


Joseph A. Bokar<sup>‡§</sup>, Mary Eileen Rath-Shambaugh, Rachael Ludwiczak, Prema Narayan<sup>¶</sup>, and Fritz Rottman<sup>||</sup>

From the Department of Molecular Biology and Microbiology and the <sup>‡</sup>Department of Internal Medicine, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106

## Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase

J. A. Bokar, M. E. Shambaugh, D. Polayes, A. G. Matera and F. M. Rottman

RNA 1997 3: 1233-1247




# A new.... old phenomenon



**1974-2012: m<sup>6</sup>A modification in mRNA was believed not biological relevant**

Reasons:

- contamination artefact,
- mutation of specific m<sup>6</sup>A sites in viral RNA did not affect processing or the viral lifecycle (Kane and Beemon, 1987),
- no methods for global detection of m<sup>6</sup>A sites in the transcriptome.



# A new.... old phenomenon




Before 2012, the genome-wide distribution of m<sup>6</sup>A was unknown, until two independent studies developed an m<sup>6</sup>A RNA immunoprecipitation approach followed by high-throughput sequencing (MeRIP-seq) to map the m<sup>6</sup>A RNA methylomes with a ~100-nucleotide resolution. Numerous other methodologies have since followed over the years.



# Methods for detecting m<sup>6</sup>A

2012

## MeRIP-Seq / m<sup>6</sup>A-Seq




Resolution: ~100 nucleotides



- ~10,000 sites identified, average ~3 m<sup>6</sup>A sites/transcript.
- Enrichment around the STOP codon (mRNA) or last exon (mRNA and lncRNA).
- 20% DRACH sequences modified.

# Methods for detecting m<sup>6</sup>A


MeRIP-qPCR is suitable for m<sup>6</sup>A identification at single mRNA target. MeRIP-qPCR uses premixed m<sup>6</sup>A antibody immunobeads to obtain full-length m<sup>6</sup>A modified mRNA from total RNA directly. The enriched RNA-antibody complex is first digested by protease to remove antibodies, and then the mRNA is subjected to qPCR. The MeRIP-Seq/m<sup>6</sup>A-seq method can identify m<sup>6</sup>A mRNA modifications, and then MeRIP- qPCR can verify the accuracy of results while studying the function of m<sup>6</sup>A modifications on specific transcripts. The combination of MeRIP-Seq/m<sup>6</sup>A-seq and meRIP-qPCR is suitable for studying the majority of m<sup>6</sup>A mRNA modifications.





# Methods for detecting m<sup>6</sup>A

2023

## m<sup>6</sup>A mapping by glyoxal and nitrite-mediated adenosine deamination (GLORI)




Resolution: single nucleotide




- >200,000 identified, average ~10 m<sup>6</sup>A sites/transcript with several genes possessing even more than 100 modification sites.
- Enrichment around the STOP codon (mRNA) or last exon (mRNA and lncRNA).
- 40% DRACH sequences modified.

# Methods for detecting m<sup>6</sup>A


Direct detection of RNA modification using nanopore sequencing has many advantages over NGS. No PCR amplification is required during sequencing, so there is no PCR bias. It can also identify multiple m<sup>6</sup>A modification sites on a single RNA and multiple RNA modifications simultaneously in one experiment. However, some RNA modifications cause only small current changes, making it difficult to distinguish accurately between certain modifications, and potentially leads to high false positive rates. Computational methods have been developed based on the property that RNA modification causes an increase of “error” in the output of the base-calling algorithm.




# m<sup>6</sup>A writers, erasers and readers



- b**
- |   |   |  |
|---|---|--|
| <p><b>Transcription silencing</b></p> <ul style="list-style-type: none"> <li>• YTHDC1</li> </ul>                      | <p><b>Nuclear export</b></p> <ul style="list-style-type: none"> <li>• YTHDC1</li> </ul>   | <p><b>Translation</b></p> <ul style="list-style-type: none"> <li>• YTHDF1</li> <li>• YTHDF3</li> <li>• eIF3</li> </ul> |
| <p><b>Transcription activation</b></p> <ul style="list-style-type: none"> <li>• YTHDC1</li> </ul>                     | <p><b>RNA stability and decay</b></p> <ul style="list-style-type: none"> <li>• YTHDF2</li> <li>• YTHDF1</li> <li>• YTHDC1</li> <li>• IGF2BP1</li> <li>• IGF2BP2</li> <li>• IGF2BP3</li> </ul> | <p><b>miRNA biogenesis</b></p> <ul style="list-style-type: none"> <li>• HNRNPA2B1</li> </ul>                           |
| <p><b>Splicing</b></p> <ul style="list-style-type: none"> <li>• YTHDC1</li> <li>• HNRNPC</li> <li>• HNRNPG</li> </ul> |   | <p><b>Alternative polyA</b></p> <ul style="list-style-type: none"> <li>• YTHDC1</li> </ul>                             |




# METTL3 is the catalytic subunit of the complex




METTL14 has a degenerate active site and plays non-catalytic roles in maintaining complex integrity and substrate RNA binding.

The RNA binding activity of METTL3 depends on the presence of a conserved cluster of positively charged residues across the METTL3/METTL14 heterodimer interface and a N-terminal Zinc finger domain in the METTL3 protein



# The m<sup>6</sup>A writer-complex components

The m<sup>6</sup>A writer complex is regulated by the MACOM complex, which contains diverse proteins. Depletion of MACOM components inhibits m<sup>6</sup>A methylation. Why m<sup>6</sup>A formation is mediated by such a large complex is not known, but the individual proteins probably have specific functions or may integrate different cellular signals in order to regulate methylation.



# m<sup>6</sup>A writers show evolutionary conservation and important biological roles

Species	Methyltransferases	Auxiliary factors	Biological roles
<i>Saccharomyces cerevisiae</i>	IME4	MUM2, SLZ1	Required for meiosis and sporulation (Clancy et al. 2002). SLZ1 localizes the complex to the nucleolus for m <sup>6</sup> A methylation (Schwartz et al. 2013).
<i>Drosophila melanogaster</i>	IME4	FL(2)D	IME4 is essential for viability (Hongay and Orr-Weaver 2011). IME4 is required for Notch signaling during oogenesis (Hongay and Orr-Weaver 2011). FL(2)D is required for splicing of <i>Sxl</i> and <i>tra</i> pre-mRNAs that are responsible for sexual determination (Penalva et al. 2000).
<i>Arabidopsis thaliana</i>	MTA	FIP37	Required for embryonic development (Zhong et al. 2008). Required for normal growth patterns, apical dominance, and plant development (Bodi et al. 2012).
<i>Danio rerio</i>	METTL3, METTL14	WTAP	METTL3 and WTAP are required for normal embryogenesis (Ping et al. 2014).
Mammals	METTL3, METTL14	WTAP	METTL3 and METTL14 regulate stem cell differentiation and reprogramming (Batista et al. 2014; Wang et al. 2014b; Geula et al. 2015). METTL3 regulates circadian periods (Fustin et al. 2013). Depletion of METTL3 and METTL14 leads to apoptosis in cancer cells (Bokar 2005). WTAP localizes METTL3–METTL14 to nucleus speckles (Ping et al. 2014). WTAP regulates cell cycle, splicing, and embryonic development (Horiuchi et al. 2006, 2013; Ping et al. 2014).

METTL3 knock-out mice exhibit embryonic lethality between E3.5 and E8.5.


# m<sup>6</sup>A writers show evolutionary conservation and important biological roles

Protein	Genetic alteration (method)	System	Phenotypes
METTL3	RNA interference (Morpholino)	Zebrafish embryo	<ul style="list-style-type: none"> <li>• Endothelial-to-hematopoietic transition ↓</li> <li>• HSPC emergence ↓</li> </ul>
	Endothelial KO ( <i>Vec-Cre</i> )	Murine embryo (E10.5 AGM)	<ul style="list-style-type: none"> <li>• HSPC and HEC frequency ↓</li> <li>• In vitro CFU-forming ability and in vivo repopulating ability ↓</li> </ul>
	Hematopoietic KO ( <i>Vav-Cre</i> )	Murine embryo (E14.5 fetal liver)	<ul style="list-style-type: none"> <li>• BM failure and perinatal lethality in homozygous knockout embryos</li> <li>• Cellularity, erythroid maturation, terminal myeloid differentiation ↓</li> <li>• LSK and LT-HSC absolute number ↑</li> <li>• In vitro CFU-forming and serial replating ability ↓</li> <li>• In vivo repopulating ability ↓</li> </ul>
	pIpC-inducible KO ( <i>Mx1-Cre</i> )	Adult mouse	<ul style="list-style-type: none"> <li>• Pancytopenia, splenomegaly, extramedullary hematopoiesis</li> <li>• BM cellularity, terminal differentiation of megakaryocyte and erythroid ↓</li> <li>• BM phenotypic HSC frequency and absolute number ↑</li> <li>• In vitro CFU-forming ability of HSCs ↓</li> <li>• In vivo repopulating ability of purified HSCs ↓</li> </ul>
	Myeloid KO ( <i>Lysm-Cre</i> )	Adult mouse	<ul style="list-style-type: none"> <li>• BM and SP cellularity, complete blood count, no<sup>Δ</sup></li> <li>• Homeostatic and lipopolysaccharide-induced myelopoiesis, no<sup>Δ</sup></li> </ul>
	RNA interference (shRNA)	Human CD34 <sup>+</sup> HSPC (cultured ex vivo)	<ul style="list-style-type: none"> <li>• CFU-forming ability and cell growth ↓</li> <li>• Apoptosis, no<sup>Δ</sup></li> <li>• Myeloid differentiation ↑</li> </ul>
METTL14	Tamoxifen-inducible KO ( <i>Cre<sup>ERT</sup></i> )	Adult mouse	<ul style="list-style-type: none"> <li>• Complete blood count, no<sup>Δ</sup></li> <li>• In vivo repopulating ability of BM cells ↓</li> </ul>
	pIpC-inducible KO ( <i>Mx1-Cre</i> )	Adult mouse	<ul style="list-style-type: none"> <li>• BM cellularity and BM LSK frequency, no<sup>Δ</sup></li> <li>• In vivo long-term repopulating ability of BM cells ↓</li> </ul>
	RNA interference (shRNA)	Human CD34 <sup>+</sup> HSPC (induced toward myelopoiesis ex vivo)	<ul style="list-style-type: none"> <li>• CFU-forming ability ↓</li> <li>• Cell growth, apoptosis, no<sup>Δ</sup></li> <li>• Monocytic differentiation ↑</li> </ul>

# m<sup>6</sup>A erasers

FTO and ALKBH5 belong to the AlkB family of Fe(II) and  $\alpha$ -ketoglutarate-dependent dioxygenases, capable of removing alkyl adducts from bases through oxidative demethylation.

FTO, and ALKBH5 exhibit differences in intracellular functions and biological roles, likely stemming from variances in structure, substrate selection, cellular localization, and protein interactions.




DSBH represents the double-stranded  $\beta$ -helix domain, NOG stands for the N-oxoglutarate binding domain, and CTD represents the carboxyl-terminal domain. The nuclear localization signal is the specific NLS sequence in the NOG structure of FTO

# m<sup>6</sup>A erasers

<b>Protein</b>	<b>FTO</b>	<b>ALKBH5</b>
<b>Target</b>	ssDNA, ssRNA m <sup>6</sup> A, m <sup>6</sup> Am, m <sup>1</sup> A	ssDNA, ssRNA m <sup>6</sup> A
<b>Localization</b>	Nucleus, cytoplasm	Nucleus
<b>Function in tissues</b>	Alternative splicing, regulates cap-independent translation upon heat shock, affects neuronal development	mRNA export, splicing in mouse male germ cells
<b>KO phenotype in mouse</b>	Impaired adipocytes differentiation, lean phenotype, growth retardation	Infertility and impaired spermatogenesis
<b>Highest expression</b>	Brain	Testis
<b>Connection with disease</b>	Neuronal and metabolic defects, AML, breast cancer, glioblastoma	Breast cancer, glioblastoma, infertility




# The m<sup>6</sup>A mRNA life cycle



**METTL3** is the m<sup>6</sup>A methylases specific for mRNA (99%), **METTL16** for U6 snRNA and few mRNAs (1%), while ZCCHC4 and METTL5 are specific for rRNAs.


# Factors influencing m<sup>6</sup>A deposition

- METTL3/14 recruitment by TFs
- Histone modifications
- RNA Pol II elongation rate
- Nuclear retention
- EJC and SR protein deposition
- METTL3/14 recruitment by RBPs




# $m^6A$ methylation affects protein-RNA interactions through multiple mechanisms

- Methylation can perturb the secondary structure of mRNA, exposing or masking potential RNA-binding motifs.
- Selective  $m^6A$ -binding proteins exhibit increased affinity for methylated mRNAs and in turn incorporate these transcripts into various steps of mRNA metabolism.



# $m^6A$ can disrupt RNA structures that are dependent on Hoogsteen base pair




# $N^6$ -methyladenosine-dependent RNA structural switches regulate RNA-protein interactions

Nian Liu<sup>1</sup>, Qing Dai<sup>1</sup>, Guanqun Zheng<sup>2</sup>, Chuan He<sup>1,2,3,4</sup>, Marc Parisien<sup>2†</sup> & Tao Pan<sup>2,3</sup>



*Nature* **518**, 560–564. 2015

$m^6A$  alters the local structure in mRNA and lncRNA to facilitate binding of heterogeneous nuclear ribonucleoprotein C (HNRNPC), an abundant nuclear RNA-binding protein responsible for pre-mRNA processing. Thus, affecting the abundance as well as alternative splicing of target mRNAs.



“ $m^6A$  switch”

# m<sup>6</sup>A readers



## Transcription silencing

- YTHDC1

## Transcription activation

- YTHDC1

## Splicing

- YTHDC1
- HNRNPC
- HNRNPG

## Nuclear export

- YTHDC1

## RNA stability and decay

- YTHDF2
- YTHDF1
- YTHDC1
- IGF2BP1
- IGF2BP2
- IGF2BP3

## Translation

- YTHDF1
- YTHDF3
- eIF3

## miRNA biogenesis

- HNRNPA2B1

## Alternative polyA


- YTHDC1

- Indirect reader proteins
- Direct reader proteins

# m<sup>6</sup>A direct readers


RNA pull-down experiments, using methylated and control versions of an RNA bait followed by mass spectrometry, was used to identify novel m<sup>6</sup>A-binding proteins.

Three cytoplasmic proteins of the YTH domain family, **YTHDF1–3**, have been identified as selective m<sup>6</sup>A-binding proteins in mammalian cell extracts.




Overlap between YTH binding consensus (yellow) and methylation consensus (red)

# m<sup>6</sup>A direct readers




YTHDC1 appears to be the only nuclear reader, while the YTHDF proteins bind predominantly to m<sup>6</sup>A in cytoplasmic mRNAs.




The YTH domain is highly conserved with more than 86% identity

# m<sup>6</sup>A direct readers

The YTH domain hosts the m<sup>6</sup>A recognition site within the aromatic cage. The m<sup>6</sup>A moiety fits into a small pocket lined with hydrophobic residues (0.1-3 μM), including one tyrosine and two or three tryptophan residues (i.e., Trp411 and Trp470 in YTHDF1, Trp432 and Trp491 in YTHDF2, Trp438 and Trp497 in YTHDF3). YTH specificity is not restricted to the m<sup>6</sup>A moiety; it can also recognise with lower affinity m<sup>1</sup>A and m<sup>5</sup>C (KD m<sup>1</sup>A = 5.8 ± 1.7 μM; KDm<sup>5</sup>C = 17.3 ± 4 μM). YTH domain does not require a specific *consensus* sequence for binding.



# m<sup>6</sup>A direct readers



The N- and C-terminal regions, termed Low Complexity Domains (LCDs), exhibit disordered structural organisation and limited sequence similarity, particularly among YTHDFs (49-52%). These regions determine paralog identity and are thought to mediate interactions with specific effector proteins within dynamic, subcellular, membraneless condensates by liquid-liquid phase separation LLPS, such as P-bodies and SG

# Consequences of m6A methylation on gene expression

m<sup>6</sup>A modification on pre-mRNA and mRNA may produce different outputs, including:

- **regulation of transcription and chromatin modifications**
- **regulation of alternative splicing and polyadenylation**
- **regulation of mRNA stability**
- **regulation of mRNA translation**
- **enhanced mRNA export**
- **increased nuclear microRNA processing**


# **Regulation of transcription and chromatin modifications**

# Nuclear m<sup>6</sup>A reader YTHDC1 regulates, transcription, alternative splicing and polyadenylation

- YTHDC1 is essential for embryo viability and is required for oocyte growth and maturation.
- YTHDC1 interacts with m<sup>6</sup>A-modified RNAs to regulate multiple steps of RNA metabolism in the nucleus.
- YTHDC1 is widely associated with transcriptional activation (via enhancer RNA-mediated crossregulation with active epigenetic marks).
- YTHDC1 transcriptional repressive action is largely associated with transposable elements and long ncRNAs.
- The diversity in YTHDC1–m<sup>6</sup>A functions is linked to their ability to promote membraneless nuclear subcompartments, such as the nuclear speckles.
- YTHDC1 also regulates alternative splicing and polyadenylation


# Distinct molecular mechanisms associated with YTHDC1 nuclear and chromatin regulation

(1) **Transcriptional activation** can be driven by transcriptional condensates formed by the multivalent interaction of YTHDC1–m<sup>6</sup>A–enhancer RNAs and the BRD4 transcriptional activator, regulation of promoter-proximal pausing of RNAPII (Drosophila S2R cells), or de-repression via KDM3B interaction which promotes the removal of H3K9me<sub>2</sub> repressive marks (mESCs). (2) **Transcriptional silencing** by YTHDC1 predominantly targets ncRNAs and transposable elements as m<sup>6</sup>A targets. Recruitment of YTHDC1 to m<sup>6</sup>A-modified retrotransposon transcripts triggers heterochromatin formation in mESCs, acting in cis in regulating the intracisternal A-type particle (IAP, bottom), a type of endogenous retroviral sequences, and in trans (top) via direct interaction with SETDB1 and TRIM28, which leads to the deposition of H3K9me<sub>3</sub>. YTHDC1 and METTL3 interaction provides positive feedback to enhance m<sup>6</sup>A-associated local heterochromatin formation (mESCs). (3) Further gene repression in mESCs can be achieved by **degradation of regulatory RNAs** termed chromatin-associated RNAs (caRNAs), which have chromatin relaxation activity, including LINE-1 (mESCs). (4) **Nuclear condensates** induced by YTHDC1 phase separation with m<sup>6</sup>A-RNAs and other IDR-containing nuclear proteins can modulate nuclear processing via spatial control of gene expression.




# YTHDC1 promotes XIST-mediated transcriptional repression

*XIST* is highly methylated with at least 78 m<sup>6</sup>A. RBM15 binding enables methylation of adjacent adenosine residues in DRACH consensus sites. Knockdown of RBM15 and RBM15B, or knockdown of METTL3 impairs *XIST*-mediated gene silencing. The m<sup>6</sup>A residues act as recruitment sites for YTHDC1, which may facilitate and stabilize the assembly of silencing proteins on *XIST*.



# m<sup>6</sup>A and R-loop regulation


m<sup>6</sup>A modification has also been found enriched in R-loop and plays a role in maintaining genome stability and facilitating transcription termination. YTHDC1 recognizes m<sup>6</sup>A-modified R-loops and participates in DNA damage responses induced by R-loops. Although the consequences of m<sup>6</sup>A-deficiency in DNA damage are consistent in many studies (e.g. increased sensitivity to DNA damaging agents), the role of RNA m<sup>6</sup>A modification in R-loops formation remains to be further clarified.





# **Regulation of alternative splicing and polyadenylation**

# YTHDC1 regulates alternative pre-mRNA splicing

YTHDC1 promotes exon inclusion of targeted mRNAs through facilitating SRSF3 while blocking SRSF10 mRNA binding. YTHDC1 directly regulates mRNA splicing by bridging interactions of *trans*- and *cis*- regulatory elements.



# YTHDC1 is required for female-specific alternative splicing of *Sxl*




Female splicing

# YTHDC1 regulates alternative polyadenylation

A. YTHDC1 is associated with Pol II during transcription by interacting with MTC and binds to the modification sites upstream of proximal APA sites when m<sup>6</sup>A modification is finished. Then, YTHDC1 interacts with FIP1L1 and disrupts the recruitment of CPSF4 and other CPSF factors, resulting in the suppression of proximal APA sites and longer 3' UTRs.


B. This inhibition is abrogated at low levels of YTHDC1 or in the absence of m<sup>6</sup>A modification. FIP1L1 interacts with CPSF4, which recruits other CPSF factors and promotes the usage of proximal APA sites, resulting in shortened 3' UTRs.



# Regulation of mRNA stability

# m<sup>6</sup>A-mediated RNA degradation


## Deadenylation




## Endoribonucleolytic cleavage




## Decapping



## CDS-m<sup>6</sup>A decay (CMD)





# Methodologies for identifying YTHDF2-regulated RNA targets



# YTHDF2 stimulates mRNA degradation



- YTHDF2 knockdown led to prolonged (~30% in average) lifetimes of its mRNA targets in comparison to non target mRNAs (RNA-seq data on YTHDF2 knockdown and control samples obtained at different time points after transcription inhibition with actinomycin D).
- Overexpression of full-length YTHDF2 in HeLa cells led to reduced levels of m<sup>6</sup>A after 24 h (measured by LC-MS), whereas overexpression of N-YTHDF2 or C-YTHDF2 increased the m<sup>6</sup>A/A ratio of the total mRNA (a, b).
- Tethering YTHDF2-λ to F-luc-5BoxB (five Box B sequence was inserted into the 3' UTR of the mRNA reporter) led to a significantly reduced mRNA level (f).



1: λ  
2: YTHDF2-λ  
3: YTHDF2



# YTHDF2 induces mRNA localization to P bodies

Via its P/Q/N-rich N-terminal domain, YTHDF2 localizes to processing bodies (P bodies) in the cytoplasm where mRNA turnover factors are concentrated.



# YTHDF2 stimulates mRNA degradation

YTHDF2 interactors were identified by Co-IP or Proximity-dependent Bioin identification (BioID)



# YTHDF2 stimulates mRNA degradation


YTHDF2 recognizes m<sup>6</sup>A in mRNAs by its C-terminal YTH domain. Then, the N-terminal half of YTHDF2 recruits various effectors, such as UPF1, HRSP12, and/or CNOT1, to trigger rapid degradation of m<sup>6</sup>A mRNAs through one of the three following pathways:

i) decapping followed by 5'-to-3' exoribonucleolytic cleavage via the YTHDF2-UPF1-PNRC2-DCP1A axis,

ii) endoribonucleolytic cleavage via the YTHDF2-HRSP12-RNase P/MRP axis, and


iii) deadenylation followed by 3'-to-5' exoribonucleolytic cleavage via the YTHDF2-CCR4-NOT axis.

iv) P-body translocation




# YTHDF2 Exerts Essential Functions in mouse Female Fertility


Knockout of *Ythdf2* revealed that depletion of YTHDF2 causes female-specific infertility despite successful ovulation. YTHDF2 regulates transcript degradation during oocyte maturation, which is essential for the competence of oocytes to sustain early zygotic development. *Ythdf2*-KO male mice showed mild degenerative changes in the seminiferous tubules. Accordingly, these males were hypofertile. *Ythdf2* heterozygote mice need at least one functional copy of another *Ythdf* reader to escape embryonic mortality.




# mRNA half-life is primarily dictated by m<sup>6</sup>A




## mRNA dosage regulation



## RNA surveillance




# RNA Modification Groups Transcripts for Cellular Processes



# CDS-m<sup>6</sup>A decay (CMD)

m<sup>6</sup>A sites in the coding sequence trigger **CDS-m<sup>6</sup>A decay (CMD)**, a pathway that is distinct from previously reported m<sup>6</sup>A-dependent degradation mechanisms. Mechanistically, CMD depends on translation, whereby m<sup>6</sup>A deposition in the CDS triggers ribosome pausing and transcript destabilization. The subsequent decay involves the translocation of the CMD target transcripts to P-bodies and recruitment of the m<sup>6</sup>A reader YTHDF2.






## Article

**tRNA modifications tune m<sup>6</sup>A-dependent mRNA decay**


Bastian Linder,<sup>1,11,10</sup> Puneet Sharma,<sup>2,3,10</sup> Jie Wu,<sup>2,3,4,9,10</sup> Tosca Birbaumer,<sup>3,4</sup> Cristian Eggers,<sup>3</sup> Shino Murakami,<sup>5</sup> Roman E. Ott,<sup>3</sup> Kai Fenzl,<sup>1</sup> Hannah Vorgerd,<sup>2</sup> Florian Erhard,<sup>6,7</sup> Samie R. Jaffrey,<sup>5</sup> Sebastian A. Leidel,<sup>2,3,12,\*</sup> and Lars M. Steinmetz<sup>1,8,9,\*</sup>

Codons that are modified with m<sup>6</sup>A are decoded inefficiently by the ribosome, rendering them “non-optimal” and inducing ribosome collisions on cellular transcripts. This couples mRNA translation to decay. 5-Methoxycarbonylmethyl-2-thiouridine (mcm<sup>5</sup>s<sup>2</sup>U) in the tRNA anticodon loop counteracts this effect. This unanticipated link between the mRNA and tRNA epitranscriptomes enables the coordinated decay of mRNA regulons, including those encoding oncogenic signaling pathways. In cancer, dysregulation of the m<sup>6</sup>A and mcm<sup>5</sup>s<sup>2</sup>U biogenesis pathways—marked by a shift toward more mcm<sup>5</sup>s<sup>2</sup>U—is associated with more aggressive tumors and poor prognosis.

**Normal tissue:****Tumor:**



# Coding sequence–m<sup>6</sup>A-dependent mRNA decay (CMD)

m<sup>6</sup>A modification within ribosomal aminoacyl (A)-site codons slows down ribosome decoding, which may result in ribosome pausing or stalling. This impaired translation can trigger downstream decay via multiple mechanisms that remain unresolved. YTHDF proteins may be recruited to stalled ribosomes or bind downstream, and either promote decay directly or via translocation to processing bodies (P-bodies). Ribosome collisions – potentially intensified by loss of tRNA modifications such as 5-methoxycarbonylmethyl-2-thiouridine (mcm<sup>5</sup>s<sup>2</sup>U) – amplify decay signals. It remains unclear whether degradation occurs at the site of pausing, within P-bodies, or both, and whether decapping enzymes such as DCP2 play a role in this process



# YTHDC2 is essential for fertility in mice

- Homozygous *Ythdc2*<sup>-/-</sup> mutant females and males are infertile.
- YTHDC2 regulates levels of m6A-modified transcripts to ensure meiosis
- YTHDC2 interacts with the 5'/3' exoribonuclease XRN1
- The function of DC2 in fertility has been recently shown to be independent from the YTH domain.




YTHDC2 is the largest member of the YTH family, is cytosolic, and expressed exclusively in the animal germline.

While its m<sup>6</sup>A-binding property is dispensable *in vivo* in mice. However, its RNA helicase activity is essential for mammalian fertility.


Biochemical studies reveal that the weak helicase activity of YTHDC2 is enhanced by its interaction with the 5'→3' exoribonuclease XRN1

Single-cell transcriptomics allowed the identification of a role for YTHDC2 in ensuring proper separation of transcriptomes when the germ cells transition from mitosis to meiosis, because mutant cells display a mixed transcriptome identity that is not conducive for proper meiotic progression

RNA helicase YTHDC2 recognizes U-rich motifs and is regulated by its interaction partners




YTHDC2 separates the mitotic and meiotic transcriptomes






# m<sup>6</sup>A-mediated RNA stabilization

Nucleus





Cytoplasm




# IGF2BPs are oncogenic m<sup>6</sup>A readers

By recruiting mRNA stabilizers, such as HuR and MATR3, IGF2BPs protect target mRNAs from degradation in the P-body while facilitating translation after being exported to the cytoplasm. In particular, IGF2BPs regulate *MYC* expression in an m<sup>6</sup>A-dependent manner.




# m<sup>6</sup>A recruits YTHDF proteins, leading to their phase separation

YTHDF (DF) proteins and YTHDC! were shown to undergo liquid–liquid phase separation (LLPS) in the presence of mRNAs containing multiple m<sup>6</sup>A residues. The low-complexity domain of each reader has the ability to mediate protein–protein interactions that induce the formation of phase-separated ‘condensates’. These DF–m<sup>6</sup>A mRNA condensates are then recruited to pre-existing membraneless compartments formed by phase separation, such as stress granules, P-bodies and neuronal RNA granules.



# YTHDC1 is required for AML cell survival and leukemogenesis


YTHDC1 undergoes liquid-liquid phase separation by binding to m6A to form dynamic nuclear condensates. These nuclear bodies are increased in acute myeloid leukemia (AML) cells and protect mRNAs (i.e., MYC and others) from the PAXT-exosome complex.



# Regulation of mRNA translation

# m<sup>6</sup>A regulates mRNA translation

- Cap -independent translation initiation (m<sup>6</sup>A in 5'-UTR)



# m<sup>6</sup>A regulates mRNA translation

- Cap -independent translation initiation (m<sup>6</sup>A in 5'-UTR)



**Molecular Cell** CellPress 2024


Short article

**N<sup>6</sup>-methyladenosine in 5' UTR does not promote translation initiation**

Matter arising

Ewelina Guca,<sup>1</sup> Rodrigo Alarcon,<sup>2</sup> Michael Z. Palo,<sup>3</sup> Leonardo Santos,<sup>2</sup> Santiago Alonso-Gil,<sup>4,5</sup> Marcos Davyt,<sup>2</sup> Leonardo H. F. de Lima,<sup>1,6</sup> Fanny Boissier,<sup>1</sup> Sarada Das,<sup>2</sup> Bojan Zagrovic,<sup>4,5</sup> Joseph D. Puglisi,<sup>3</sup> Yaser Hashem,<sup>1,\*</sup> and Zoya Ignatova<sup>2,7,\*</sup>

(c)




(d)



# m<sup>6</sup>A regulates mRNA translation


- Cap-dependent translation initiation (m<sup>6</sup>A in 3'-UTR)



# m<sup>6</sup>A regulates mRNA translation


- Translation elongation (m<sup>6</sup>A in coding regions )

*Bacteria, HEK293T, breast cancer cells, X. laevis*




(a)

*MEFs*




(b)

*AML*



(c)

*HeLa, breast cancer, gastrointestinal tumors*




(d)

*Snail, KRT7, MRP1*

# m<sup>6</sup>A regulates mRNA translation



- Translation elongation



Matter arising




# m<sup>6</sup>A regulates mRNA translation

- Direct translational regulation by m<sup>6</sup>A methyltransferases



# YTHDF1 stimulates mRNA translation


The knockdown of **YTHDF1** does not change the m<sup>6</sup>A/A ratio of total mRNA. Upon the knockdown of YTHDF1, the amount of methylated mRNA increases in mRNPs and decrease within the translating and translatable pools. These results do indicate that YTHDF1 is functionally distinct from YTHDF2 and may not be directly involved in mRNA decay.




# Proposed Model of Translation Promotion by YTHDF1

(A) YTHDF1 recruits m<sup>6</sup>A-modified transcripts to facilitate translation initiation. The association of YTHDF1 with translation initiation machinery may be dependent on the loop structure mediated by eIF4G and the interaction of YTHDF1 with eIF3.

(B) The m<sup>6</sup>A-based regulation through binding of YTHDF1 and YTHDF2 shares similarities with that of the AU-rich element which is regulated by HuR/HuD and AUF1.




# YTHDF3 facilitates translation through interacting with YTHDF1



In the reporter assay, YTHDF3N-MS2 itself did not promote translation


# All three YTHDFs contribute collectively to accelerating the metabolism of m<sup>6</sup>A-modified mRNAs in the cytosol




LC-MS/MS quantification of m<sup>6</sup>A levels of HeLa cells treated with siControl, siYTHDF1, siYTHDF2, siYTHDF3, and combinations of those oligoes.

# YTHDF3 facilitates translation and decay of m<sup>6</sup>A-modified RNA

YTHDF3 could serve as a hub for fine-tuning the RNA accessibility of YTHDF1-2. These three mRNA pools controlled by YTHDF1-3 could be interchangeable and highly dynamic, resulting in an interconnected and dynamic mRNA modulation through m<sup>6</sup>A.




# A Unified Model for the Function of YTHDF Proteins in Regulating m<sup>6</sup>A-Modified mRNA



# DF Proteins Bind the Same m<sup>6</sup>A Sites throughout the Transcriptome


YTH domains are essentially identical in structure and are expected to have the same binding specificity. The crystal structures of the YTH domain show a single RNA-binding domain, which is the m<sup>6</sup>A-binding domain.

The amino acids that contact m<sup>6</sup>A and the m<sup>6</sup>A-proximal nucleotides are conserved in the DF1, DF2, and DF3 YTH domain.





# Problem with using cutoff thresholds to call peaks

In CLIP experiments, multiple reads that overlap a specific region of a gene comprise a peak. Despite the low background in CLIP experiments, nonspecific reads are present, which therefore requires “peak calling” algorithms. These algorithms call a peak based on peak height relative to other regions in the transcript. However, some peaks are true positives (i.e., actual binding sites) and some are false positives. Therefore, a statistical cutoff threshold is used to decide which peaks will be used for further analysis. Since the cutoff threshold is arbitrary, a slightly lower threshold would have called both peaks. Thus, using cutoffs creates an incorrect impression that an mRNA binds one YTHDF protein and not the other.





# DF proteins bind the same m<sup>6</sup>A sites throughout the transcriptome

By using a correlation of read numbers at predicted binding sites, DF1, DF2, and DF3 have similar binding preferences for different m<sup>6</sup>A submotifs. Shown is the prevalence of different binding sites recognized by DF1, DF2, and DF3 based on iCLIP binding data (B). DF1, DF2, and DF3 iCLIP reads show a similar distribution in mRNAs that resembles the miCLIP read distribution. Shown are representative examples of DF1, DF2, and DF3 iCLIP read distribution and miCLIP read distribution on HNRNPF and MDM2. The iCLIP and miCLIP data shown here were obtained in HEK293T cells and were similar to data obtained in HeLa cells (C).





# The combined activity of DF proteins leads to degradation of m<sup>6</sup>A-modified mRNA

As in a previous study, they found no effect of DF1 depletion on m<sup>6</sup>A-mRNA abundance compared with non-methylated mRNAs. In contrast, as reported previously, depletion of DF2, the most highly expressed DF paralog in HeLa cells was associated with a small but statistically significant increase in the abundance of m<sup>6</sup>A-mRNAs. No increase in m<sup>6</sup>A-mRNA abundance was observed following DF3 depletion which, like DF1, is more lowly expressed in HeLa cells. However, knockdown of any of the DF paralogs was associated with a compensatory increase in the expression of the other paralogs. Thus, compensatory upregulation of the other DF paralogs could further mask an effect of knockdown. Knocking down any two DF paralogs increased the overall abundance of m<sup>6</sup>A-mRNA. Importantly, the selective increase in m<sup>6</sup>A-mRNA expression was largest upon triple knock-down, and, in each case, it was directly correlated with the number of m<sup>6</sup>A sites per mRNA



# DF paralogs do not affect the translation of m<sup>6</sup>A-modified mRNAs


They reanalyzed published dataset of ribosome footprinting. The number of ribosome-protected fragments bound to each mRNA was normalized to the abundance of the respective mRNA to calculate translation efficiency (TE). The TE of m<sup>6</sup>A-mRNAs is not reduced upon silencing of *DF1* or any DF paralog.




mRNAs were binned based on the number of m<sup>6</sup>A sites. The distribution of each of m<sup>6</sup>A mRNA subgroups is quantified in the boxplots.

# A Unified Model for the Function of YTHDF Proteins in Regulating m<sup>6</sup>A-Modified mRNA

The three DF proteins function together to mediate degradation of m<sup>6</sup>A-containing mRNAs. However, depletion of different DF paralogs can have different effects. This is because DF proteins exhibit markedly different expression levels. Therefore, depletion of a low-abundance DF paralog, such as DF3, is likely to only affect a small number of highly sensitive mRNAs, whereas depletion of a higher-abundance DF paralog would affect a larger sub- set of mRNAs, causing a different phenotype. Additionally, because DF paralogs may be expressed at different levels in different tissues, single DF paralog depletion can result in tissue-specific phenotypes




# Oncogenic roles of m<sup>6</sup>A modifiers




Targets positively regulated (upregulated) by m<sup>6</sup>A modifiers are in red, while negatively regulated (downregulated) targets are in blue.

# m<sup>6</sup>A is a good therapeutic target in leukemias



# Small-molecule inhibitors targeting m6A modifiers



# COMPANIES TARGETING RNA EPIGENETICS

Company	Named targets	Likely lead indication	Estimated phase I trial start date
STORM Therapeutics	METTL3, other methyl transferases	AML <sup>a</sup>	2021 <sup>a</sup>
Accent Therapeutics	METTL3, ADAR1	AML <sup>a</sup> , NSCLC <sup>a</sup>	2021 <sup>a</sup> , 2022 <sup>b</sup>
Gotham Therapeutics	METTL3, undisclosed 'reader', undisclosed 'eraser'	AML <sup>a</sup>	2021 <sup>a</sup>
EPICS Therapeutics	Undisclosed RNA modifying enzymes	Cancer	ND
Twentyeight-Seven Therapeutics	Undisclosed RNA modifying enzymes	Cancer	ND
Korro Bio	ADAR1	ND	ND

9th October 2024

**STORM Therapeutics to Present Phase 1 Data on its First-in-Class Lead Product STC-15 at EORTC-NCI-AACR Symposium**

11th November 2024

**STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024**

*STC-15 is well tolerated and demonstrates promising signs of clinical activity observed in multiple tumor types*

27th May 2025

**STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZI® and Appointment of Atif Abbas, M.D., as Chief Medical Officer**


*STC-15 has demonstrated durable clinical activity and tolerability to progress into a combination study with a checkpoint inhibitor*

16th April 2026

**STORM Therapeutics Secures \$56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC-15**

AML, acute myeloid leukaemia. <sup>a</sup>For METTL3 inhibitor. <sup>b</sup>For ADAR1 inhibitor. ND, no data available.

# m<sup>6</sup>A can regulate DNA damage repair through several pathways




**a)** METTL3 recruitment on chromatin is coordinated by distinct mechanisms. First, DSBs (DNA Double-Strand Breaks) are recognized by ATM, which subsequently phosphorylates and activates METTL3. Additionally, PARP1 auto-PARylation leads to its activation and subsequent binding to the METTL3 promoter, making it transcriptionally competent and upregulating METTL3 mRNA. PARP1 also mediates PARylation at damaged sites, thereby rendering them permissive for METTL3 loading. Alternatively, METTL3 recruitment can also be mediated by TonEBP (which recognizes R-loops) and ARID1A (a component of the SWI/SNF chromatin-remodeling complex).


**b)** While on chromatin, METTL3 engages Pol  $\kappa$  (Polymerase Kappa) and methylates RNAs within DNA:RNA hybrids, subsequently recruiting the DNA repair machinery through the m<sup>6</sup>A readers YTHDC1 and IGF2BP2.

**c)** METTL3 also acts directly on mRNAs of genes involved in the DNA Damage Response (DDR-related RNAs), modulating their expression.


# DNA damaging therapies in cancer patients




*Homologous recombination proficiency (HRP) status*



*Homologous recombination deficiency (HRD) status*




# METTL3 inhibition increases the response to DNA damage-based treatment




# Synonymous mutations promote tumorigenesis by disrupting m<sup>6</sup>A-dependent mRNA metabolism

Cancer cells acquire numerous mutations during tumorigenesis, including synonymous mutations that do not change the amino acid sequence of a protein. These mutations, called “m<sup>6</sup>A disruption mutations (m<sup>6</sup>A-DMs), can potentially perturb m<sup>6</sup>A modification patterns, thus altering mRNA expression levels.






GO enrichment analysis for the top 100 genes with the highest observed m<sup>6</sup>A-DM rates.






# BRCA2 is a relevant sm<sup>6</sup>A-DM-containing genes

The BRCA2-c.A1365 mutation (1365A>G) was identified in prostate cancer. They utilized a knockin approach to generate the BRCA2-c.A1365G mutation in the prostate cancer cell line PC-3. BRCA2 mRNA stability and BRCA2 protein levels were downregulated in cells with the BRCA2- c.A1365G mutation.



# BRCA2 is a relevant $m^6A$ -DM-containing genes


Given that deficiencies in BRCA1 and BRCA2 sensitize cancer cells to poly (ADP-ribose) polymerase inhibitors (PARPis), loss of  $m^6A$  at this site increased cancer cell sensitivity to the PARPi Olaparib.




# **Catalytic independent role of METTL3 in cancer**

# The m<sup>6</sup>A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells

In human cancer cells (lung cancer and myeloid leukemia) METTL3 is mislocalised in the cytoplasm and interacts with translation initiation machinery to promote translation of a subset of m<sup>6</sup>A containing mRNAs independently of its methyltransferase activity and m<sup>6</sup>A readers.




Myeloid leukemia cell line




Lung cancer cell line

# METTL3 promotes translation of a large subset of mRNAs




METTL3 depletion caused an increase in the 80S ribosome peak and a corresponding reduction of polyribosome peak (A). METTL3 depletion had a negligible effect on steady-state mRNA abundance whereas translation efficiency of a large subset (4,267) of mRNAs was reduced by at least twofold in METTL3-depleted cells (B and C). Comparison of these genes with previously reported METTL3 photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) data identified 809 mRNAs that are both bound and translationally regulated by METTL3 (D).

# METTL3 promotes translation of a large subset of mRNAs



# METTL3 enhances translation of target mRNAs by interacting with eIF3h


A large-scale purification and mass spectroscopy characterization of complexes containing Flag–METTL3 identified numerous translation factors. Gene Ontology analysis of the METTL3-interacting proteins identified ‘mRNA metabolic processes’, ‘RNA processing’ and ‘Translation’ as the most significantly enriched categories. Between the, they identified the translation factor eIF3.



Translation involving factors	
Name	No. of Proteins
Ribosomal proteins	87
Eukaryotic translation initiation factors	21
Eukaryotic translation elongation factors	5
Nuclear cap-binding protein, CBP80	1


# METTL3 enhances translation of target mRNAs by interacting with eIF3h

To test whether METTL3 interacts with any of the 13 subunit(s) of eIF3, recombinant METTL3 and 1–200 a.a. (a fragment of METTL3 that promote translation) were used for far-western blotting with a purified human eIF3 complex (c). METTL3 and 1–200 a.a. both specifically bound to a single band that probably corresponds to eIF3g, eIF3h, eIF3i, eIF3j or eIF3m. To further confirm this interaction and to define the particular subunit(s) that interacts with METTL3, they individually expressed and purified the GST-tagged eIF3 subunits from bacteria and tested them for binding to His–METTL3 by GST-pull-down (e). METTL3 (and 1–200 a.a.) were found to specifically interact with eIF3h.





# METTL3 promotes translation when tethered to a reporter mRNAs

Tethering assay to measure translation efficiency of reporter mRNAs (b, d). 1–200 a.a. fragment can promote translation in tethering experiments whereas 1–150 a.a. does not. They reasoned that a region between 150–200 a.a. must be important for the physical and functional METTL3–eIF3h.




# Identification of a conserved alanine residue in the N-terminal region of METTL3 required for its interaction with eIF3h

Secondary structure predictions identified a putative alpha helix (150–161 a.a.) that is highly conserved in mammals. Moreover, 3D modelling identified a putative structured module (c). They therefore generated a mutant version of METTL3 with a single amino acid substitution of a highly conserved alanine (A155P) to disrupt this putative helical structure. Co-immunoprecipitation confirmed substantially impaired interaction of METTL3(A155P) with translation initiation factors (not shown). Tethering experiments demonstrated that the METTL3(A155P) mutant is strongly impaired in promoting mRNA translation (d).



# METTL3 promotes tumorigenesis


The oncogenic function of METTL3 was studied in the mouse xenografts. NIH-3T3 cells with ectopic expression of wild-type METTL3, METTL3(A155P) or the empty-vector control were injected into nude mice to determine their *in vivo* tumorigenic capacities. Overexpression of wild-type METTL3 promoted *in vivo* tumour growth, whereas METTL3(A155P) showed an impaired ability to promote tumour growth.



**m6A promotes mRNA export**


# Inhibition of m<sup>6</sup>A-RNA Methylation Delays mRNA Export

*Mettl3* knockdown by siRNA(#48) leads to overall RNA nuclear retention, whereas depletion of ALKBH5 enhanced mRNA export to the cytoplasm. Mechanistic details are yet to be reported, but it is conceivable that nuclear readers have an active role in this process.



# The m<sup>6</sup>A machinery and mRNA export


The MACOM complex interacts with the TREX complex aiding in the export of specific mRNAs. The reader YTHDC1 associates with SRSF3. Both pathways may work in unison to recruit the export receptor NXF1(TAP)/P15 to initiate nuclear export.



**m<sup>6</sup>A promotes pri-miRNA  
processing**


# METTL3 regulates miRNA biogenesis

The m<sup>6</sup>A modification facilitates the recognition of pri-miRNA sequences and marks an initiation event in miRNA biogenesis. The m<sup>6</sup>A mark thus has an important role in the nucleus, allowing the microprocessor complex to recognize its specific substrates. Additionally, altered METTL3 expression in various human malignancies may contribute to the aberrant expression of miRNAs seen in cancer.




# HNRNPA2B1 is a nuclear reader of the m<sup>6</sup>A methylation mark

HNRNPA2B1 acts as a reader of the m<sup>6</sup>A mark in the nucleus and mediates, in part, the effects of m<sup>6</sup>A/METTL3 on microRNA processing. It is still unclear whether HNRNPA2B1 recognizes m<sup>6</sup>A residues directly, like the YTH-domain proteins, or indirectly, like the HNRNPC protein.



# The m<sup>6</sup>A Writer METTL16


Methyltransferase-like protein 16 (METTL16) is responsible for the modification of the U6 snRNA and specific mRNAs and lncRNAs containing the UACAGAGAA sequence within a specific stem-loop structure. Reader proteins cannot distinguish between METTL3- and METTL16- dependent m<sup>6</sup>A modification.



# METTL16 Regulates S-adenosylmethionine (SAM) Synthetase Intron Retention


Maintenance of proper levels of SAM is critical for a wide variety of biological processes. METTL16 regulates expression of human MAT2A, which encodes the SAM synthetase. Upon SAM depletion by methionine starvation, cells induce MAT2A expression by enhanced splicing of a retained intron.

Induction requires METTL16 and its methylation substrate, a vertebrate conserved hairpin in the MAT2A 3'-UTR. Under SAM-limiting conditions, METTL16 occupancy increases due to inefficient enzymatic turn-over, which promotes MAT2A splicing.



# METTL16 is Essential for Mouse Embryonic Development

The downregulation of the SAM synthetase *Mat2a* mRNA in *Mettl16* KO E2.5 morula is potentially a trigger for subsequent massive alteration in gene expression in the E3.5 blastocysts. Such mutant embryos fail to proceed further in development



Mendel et al., 2018. Mol Cell